documented sars-cov-2 infection ongoing or that occurred less than 3 months ago known clinical allergy to polyethylene glycol (peg) pregnant woman during first pregnancy quarter or lactating woman platelet <50 giga(g) g/l or neutrophils <0.5 g/l at time of vaccination vaccination within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection any hemorrhagic trouble considered as a contraindication to intramuscular injection history of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component participant vaccinated against tuberculosis within the past year

documented sars-cov-2 infection ongoing or that occurred less than 3 months ago known clinical allergy to polyethylene glycol (peg) pregnant woman during first pregnancy quarter or lactating woman platelet <50 giga(g) g/l or neutrophils <0.5 g/l at time of vaccination vaccination within 4 weeks from the 1st injection or planning to receive an approved vaccine 4 weeks after the last injection any hemorrhagic trouble considered as a contraindication to intramuscular injection history of severe adverse event after a vaccine administration including anaphylaxis and associated symptoms such as rash, respiratory issues, angioedema and abdominal pain, or history of allergic reaction that could be exacerbated by a vaccine component participant vaccinated against tuberculosis within the past year